Trials / Completed
CompletedNCT01290965
Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients
A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Effect of Treatment With SCY 635 on Plasma HCV RNA Following 15 Days of Oral Administration in Adult Patients With Chronic Hepatitis C Infection
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Scynexis, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the effectiveness of 15 days of therapy with SCY-635 in reducing hepatitis C virus (HCV) RNA levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Oral tablet given once or three times daily for 15 consecutive days |
| DRUG | SCY-635 | oral capsule |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2008-12-01
- Completion
- 2009-01-01
- First posted
- 2011-02-07
- Last updated
- 2014-11-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01290965. Inclusion in this directory is not an endorsement.